Live
FierceBiotechKardigan buttons up $400M upsized IPO to power heart drugs toward phase 3FierceBiotechNovocure device fails to improve brain cancer patients’ survival in phase 3 testFierceBiotechNortiva purrs into action with long-acting Lynx platform salvaged from Langer startupEndpoints NewsInnoviva revives Lyndra's long-acting oral drug platformFierceBiotechBiogen inks $1B RayThera buyout to bag preclinical immunology assetsEndpoints NewsModerna adds commercial chief, expands Stephen Hoge's role; Reunion Neuroscience CEO departsEndpoints NewsEli Lilly's TuneLab hits 100 members, adding Chai's AI modelsCellChloroplast sunscreening by protein condensates confers high-light toleranceFierceBiotechF2G, Shionogi prep regulatory push after novel antifungal passes ph. 3 testEndpoints NewsAntifungal from F2G, Shionogi succeeds in Phase 3 studyRoche MediaPartnering for Sustainable Healthcare: Roche Stands with Taiwan to Build an Innovation-Friendly Biomedical Ecosystem - Taiwan Business TOPICSBioPharma DiveKardigan extends biotech’s streak of big IPOs with $400M haul
FierceBiotech Jan 26, 2026

Guardant Health gets FDA nod to expand use of blood test for colon cancer

Guardant Health gets FDA nod to expand use of blood test for colon cancer

Original
Body unavailable. Use the original source.